Spyre Therapeutics (SYRE) Non-Current Assets (2015 - 2025)
Spyre Therapeutics (SYRE) posted Non-Current Assets of $10000.0 for Q1 2025, little changed on a QoQ basis from $10000.0 in Q4 2024, and down 96.96% year-over-year from $329000.0 in Q1 2024.
Spyre Therapeutics (SYRE) Non-Current Assets (2015 - 2025) Analysis & Trends
Spyre Therapeutics' Non-Current Assets history runs 11 years deep, the most recent figure standing at $10000.0 for Q1 2025.
- Quarterly Non-Current Assets fell 96.96% year-over-year to $10000.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $10000.0 (down 98.53% YoY) and the FY2024 annual result came in at $10000.0, down 96.98% from the prior year.
- Non-Current Assets was $10000.0 for Q1 2025 at Spyre Therapeutics, roughly flat from $10000.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $12.6 million in Q2 2021 and bottomed at $10000.0 in Q3 2024.
- A 5-year average of $5.9 million and a median of $8.1 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2021 — Non-Current Assets rose 16.03% — and 2024, when it sank 99.24%.
- Spyre Therapeutics' Non-Current Assets stood at $11.0 million in 2021, then fell by 19.47% to $8.9 million in 2022, then slumped by 96.28% to $331000.0 in 2023, then slumped by 96.98% to $10000.0 in 2024, then changed by 0.0% to $10000.0 in 2025.
- Business Quant data shows SYRE's Non-Current Assets at $10000.0 in Q1 2025, $10000.0 in Q4 2024, and $10000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Spyre Therapeutics | 257.83 Mn | 257.83 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 10,000.00 |
| Dec 31, 2024 | 10,000.00 |
| Sep 30, 2024 | 10,000.00 |
| Jun 30, 2024 | 331,000.00 |
| Mar 31, 2024 | 329,000.00 |
| Dec 31, 2023 | 331,000.00 |
| Sep 30, 2023 | 1.32 Mn |
| Jun 30, 2023 | 3.64 Mn |
| Mar 31, 2023 | 8.08 Mn |
| Dec 31, 2022 | 8.89 Mn |
| Sep 30, 2022 | 9.35 Mn |
| Jun 30, 2022 | 10.06 Mn |
| Mar 31, 2022 | 10.57 Mn |
| Dec 31, 2021 | 11.04 Mn |
| Sep 30, 2021 | 11.55 Mn |
| Jun 30, 2021 | 12.61 Mn |
| Mar 31, 2021 | 12.20 Mn |
| Dec 31, 2020 | 11.83 Mn |
| Sep 30, 2020 | 11.23 Mn |
| Jun 30, 2020 | 11.05 Mn |